ArticleLupus science & medicine2025
Systemic lupus erythematosus comorbid with chronic spontaneous urticaria: a multicentre retrospective study.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anisakiasis: A Decade of Molecular and Diagnostic Advancements (2015-2026).International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis retrospective study aims to characterise the epidemiological features of systemic lupus erythematosus (SLE) concomitant with chronic spontaneous urticaria (CSU), examines the correlation between CSU occurrence and lupus disease activity, and identifies comorbidity patterns and risk factors associated with SLE-CSU.
methodsA total of 40 SLE patients with concomitant CSU and 160 age-matched and sex-matched SLE controls without CSU were included. The Mann-Whitney U-test was used to assess disease activity at SLE onset in both groups. A Wilcoxon signed-rank test was conducted to compare the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores before and after CSU onset in patients with SLE. χ
resultsWilcoxon signed-rank tests revealed that in the SLE-CSU group, the occurrence of CSU did not result in an increase of SLEDAI scores. Univariate analysis revealed significant differences between the SLE-CSU and SLE-only groups in the presence of cylindruria, elevated IgM, IgA, IgG, serositis, mucosal ulcers and anti-Pm-Scl antibodies (p<0.05). Multivariate logistic regression analysis identified cylindruria (OR: 6.152, CI 2.352 to 16.093, p＜0.001), elevated IgA (OR: 7.598, CI 1.194 to 48.368, p=0.032), elevated IgG (OR: 3.252, CI 1.331 to 7.946, p=0.010) and mucosal ulcers (OR: 3.838, CI 1.166 to 12.637, p=0.027) as independent risk factors for CSU occurrence in patients with SLE.
conclusionThe presence of CSU in patients with SLE does not necessarily indicate increased lupus activity. Rather, cylindruria, mucosal ulcers and elevated IgA and IgG levels were identified as independent risk factors for CSU in patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.